TY  - GEN
AU  - Harbeck,N
AU  - Alt,U
AU  - Berger,U
AU  - Krüger,A
AU  - Thomssen,C
AU  - Jänicke,F
AU  - Höfler,H
AU  - Kates,R E
AU  - Schmitt,M
TI  - Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy
SN  - 1078-0432
PY  - 2001///1004
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents, Hormonal
KW  - therapeutic use
KW  - Biomarkers, Tumor
KW  - analysis
KW  - Breast Neoplasms
KW  - drug therapy
KW  - Cathepsin B
KW  - Cathepsin D
KW  - Cathepsin L
KW  - Cathepsins
KW  - Chemotherapy, Adjuvant
KW  - Cysteine Endopeptidases
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Immunoassay
KW  - Middle Aged
KW  - Multivariate Analysis
KW  - Plasminogen Activator Inhibitor 1
KW  - Prognosis
KW  - Survival Analysis
KW  - Time Factors
KW  - Treatment Outcome
KW  - Urokinase-Type Plasminogen Activator
N1  - Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
ER  -